Get notified of page updates
Research & Clinical Trials > Search Results

Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. Sign up for our community newsletter to stay up-to-date on the latest hereditary cancer research.

How to Use Our Search and Enroll Tool

Printer Friendly Page

Featured Studies Results

Cancer: Breast | Study Type: Treatment

Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors

Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

Clinicaltrials.gov identifier:
NCT04090567

Treatment
This study will examine how Olaparib in combination with the drugs Cediranib or Ceralasertib works for patients with advanced breast cancer who have BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor

Immunotherapy and PARP Inhibitor for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with a BRCA Mutation

Immunotherapy and PARP Inhibitor for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with a BRCA Mutation

Clinicaltrials.gov identifier:
NCT04673448

Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

New Treatment  in People with Triple Negative Breast Cancer and Advanced Solid Tumors

New Treatment in People with Triple Negative Breast Cancer and Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT06022029

Treatment
Study of a new drug called ONM-501 for people with triple negative breast cancer, advanced solid tumors or lymphomas

Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer

Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer

Clinicaltrials.gov identifier:
NCT04674306

Treatment
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence.

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

Clinicaltrials.gov identifier:
NCT05417594

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

Nipple Sparing Mastectomy With Immediate Implant-Based Reconstruction for Women With Early-Stage Breast Cancer

Nipple Sparing Mastectomy With Immediate Implant-Based Reconstruction for Women With Early-Stage Breast Cancer

Clinicaltrials.gov identifier:
NCT05720039

Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

Clinicaltrials.gov identifier:
NCT02693535

Treatment
Cancer treatment study for people with advanced solid tumors

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

Clinicaltrials.gov identifier:
NCT04550494

Treatment
Treatment study for people with advanced solid tumors

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05252390

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

Clinicaltrials.gov identifier:
NCT04150042

Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation

Treating Early-Stage Breast Cancer  with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with  a BRCA or PALB2 Mutation

Treating Early-Stage Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

Clinicaltrials.gov identifier:
NCT04584255

Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

Clinicaltrials.gov identifier:
NCT04644068

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer

Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

Clinicaltrials.gov identifier:
NCT04657068

Treatment
Advanced solid tumors

If you would like a more in-depth search, visit our In-Depth Search Tool that searches for studies in FORCE’s database and in clinicaltrials.gov


Sponsored By: